NKGen Biotech administers first dose of troculeucel for FTD under FDA-cleared compassionate use
NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in natural killer cell therapy, has taken a significant step in the treatment of frontotemporal ... Read More
Atai Life Sciences acquires exclusive rights to Psilera’s DMT patent portfolio
Atai Life Sciences has taken a strategic step in expanding its position in psychedelic medicine by securing exclusive rights to Psilera Inc.’s DMT patent portfolio. ... Read More